胆囊收缩素及受体基因多态性与精神分裂症的相关性研究

目的：探讨胆囊收缩素（cholecystokinin,CCK）基因、胆囊收缩素A受体（cholecystokininAreceptor。CCKAR）基因和胆囊收缩素B受体（cholecystokinin A recepmr,CCKBR）基因多态性与精神分裂症之间的相关性。方法：采用聚合酶链式反应．限制性片段长度多态性方法,对420例精神分裂症患者（病例组）和455例健康个体（对照组）三个基因的6个单核苷酸多态性（single nucleotide polymorphism,SNPs）位点（rs11571842、rs13069836、rs1800908、rs1800857、rs1042047、rs4758092）的多态性进行检测。并比较两组人群中基因型和等位基因频率分布的差异。结果：对照组6个SNPs位点的基因型频率分布均符合Hardy-Weinbere平衡（P〉0．05）;CCKAR基因rs1800857位点基因型频率分布在精神分裂症组与正常对照组间存在显著性差异（P〈0．000）,病例组T等位基因频率显著高于对照组（P〈0．01）。结论：CCKAR基因多态性与精神分裂症相关,携带T等位基因的个体可能更容易患精神分裂症。     

ABCB_1基因C3435T多态性与耐药性癫痫的关系

目的：探讨中国粤西地区汉族人群ABCB1基因C3435T（rs1045642）的单核苷酸多态性与耐药性癫痫的关系。方法：研究对象128例,包括正常对照组60例和癫痫组68例。根据患者对抗癫痫药物的反应性将癫痫组分为耐药组（30例）和药物敏感组（38例）。提取所有研究对象外周血基因组DNA,采用PCR扩增后基因测序鉴定ABCB1基因C3435T多态性。测定该位点基因型频率和等位基因频率,并进行统计学分析。结果：各组ABCB1基因C3435T基因型频率的分布符合Hardy-Weinburg平衡,提示其来自同一孟德尔群体。正常对照组与药物敏感组及耐药组,药物敏感组与耐药组间基因型频率比较,差异均无统计学意义（P〉0.05）。正常对照组与药物敏感组及耐药组,药物敏感组与耐药组间等位基因型频率比较,差异亦无统计学意义（P〉0.05）。结论：本研究结果初步证实ABCB1基因C3435T位点多态性分布与耐药性癫痫之间无相关性。     

β2-AR基因5’-调控区-654位与-1429位单核苷酸多态性与新疆哈萨克族原发性高血压关系的研究

目的：检测β2-肾上腺素能受体（β2-AR）基因5’-调控区部分序列单核苷酸多态性（SNPs）,并探讨这些SNPs与新疆哈萨克族原发性高血压的关系。方法：应用MALDI-TOFMS方法测定β2-AR基因5’-调控区-654位与-1429位单核苷酸多态性确定SNP类型,并进行基因分型。结果：β2-AR基因5’-调控区-654位与-1429位单核苷酸多态性分别为-654位G→A、-1429位T→A碱基变异。2种SNPs基因型频率在正常人群分布符合Hardy-Weinberg平衡。其中-654位SNPs基因型GG、GA、AA频率在正常血压和高血压人群间的分布没有显著性差异（x2=1.26,df=2,P〉0.05）,位于-1429bp处SNPs基因型在2组人群中分布差异无显著性（x^2=1.85,df=2,P〉0.05）。结论：β2-AR基因-654位与-1429位SNPs可能仅为基因多态性标志。     

牙鲆MyoD基因单核苷酸多态性位点的筛选

运用PCR-SSCP技术研究100尾牙鲆(Paralichthys olivaceus)MyoD基因的单核苷酸多态性(Single nucleotide polymorphisms, SNPs), 并将筛选到的突变位点与牙鲆生长性状进行相关性分析。结果表明, 在外显子1和内含子1上存在3个SNPs, 在外显子1 (MyoD2)基因座发现3种基因型AA、AB和BB, G863A突变, 属于同义突变。在内含子MyoD4基因座检测到DD、FF、CD、CE、DE和DF型个体。利用最小二乘法研究MyoD基因多态性位点对牙鲆生长性状的影响。结果表明, 外显子1的SNPs对生长性状无显著影响(P0.05)。内含子1的SNPs对牙鲆的生长性状影响均显著(P0.05)。研究结果为SNPs位点与牙鲆生长性能关联分析奠定了基础。       

双向等位基因特异性PCR与限制性片段长度多态性基因分型方法比较

目的:比较双向等位基因特异性PCR(Bi-PASA)法与聚合酶链式反应-限制性片段长度多态性(RFLP)法对EZH2基因单核苷酸多态性(SNPs)位点rs887569基因分型结果有无差异,并用Bi-PASA法对EZH2基因rs17171119位点基因分型后分析与结直肠癌(CRC)易感性的相关性。方法:提取96名CRC患者与100名体检健康者的外周血DNA,分别用Bi-PASA法与聚合PCR-RFLP法检测EZH2基因单核苷酸多态性(SNPs)位点rs887569基因型,对两种分型结果进行比较;使用Bi-PASA法对EZH2基因rs17171119位点进行基因分型后用病例-对照方法分析该SNPs在中国人群中的分布。结果:Bi-PASA与PCR-RFLP对EZH2基因rs887569位点基因分型的准确率分别为99.5%和100%;EZH2基因的rs17171119 SNPs位点多态性与结直肠癌易感性无显著相关性(P=0.938,OR=0.846,95%CI:0.586-1.221)。结论:Bi-PASA是一种简单有效检测SNPs的方法,分型结果较为可靠;rs17171119 SNPs位点多态性与结直肠癌易感性无关,但本结论还有待更大样本量基因分型的验证。     

新疆维吾尔族人2型糖尿病患者AMPKα2基因多态性的分析研究

目的：研究腺苷酸活化蛋白激酶（AMP-activated protein kinase,AMPK）单核苷酸多态性（SNPs）rs2143754位点与新疆地区维吾尔族人2型糖尿病之间的关系。方法：以聚合酶链式反应-限制性内切酶长度多态性（polymerase chain reaction-restriction flagmerit length polymorphism,PCR-RFLP）技术,对150例2型糖尿病和150例正常对照者AMPK-rs2143754位点进行基因分型。结果：AMPKet2位点T／T、G／T和G／G基因型频率在病例组为（40％,51％和9％）,正常对照组为（28％,49％和29％）,两组基因型和等位基因频率分布差异有显著性（P〈0．05）。结论：AMPKα2多态性与新疆维吾尔族人2型糖尿病有明显相关性。     

ABCB1基因C3435T多态性与耐药性癫痫的关系

目的:探讨中国粤西地区汉族人群ABCB1基因C3435T (rs1045642)的单核苷酸多态性与耐药性癫痫的关系.方法:研究对象128例,包括正常对照组60例和癫痫组68例.根据患者对抗癫痫药物的反应性将癫痫组分为耐药组(30例)和药物敏感组(38例).提取所有研究对象外周血基因组DNA,采用PCR扩增后基因测序鉴定ABCB1基因C3435T多态性.测定该位点基因型频率和等位基因频率,并进行统计学分析.结果:各组ABCB1基因C3435T基因型频率的分布符合Hardy-Weinburg平衡,提示其来自同一孟德尔群体.正常对照组与药物敏感组及耐药组,药物敏感组与耐药组间基因型频率比较,差异均无统计学意义(P＞0.05).正常对照组与药物敏感组及耐药组,药物敏感组与耐药组间等位基因型频率比较,差异亦无统计学意义(P＞0.05).结论:本研究结果初步证实ABCB1基因C3435T位点多态性分布与耐药性癫痫之间无相关性.     

水稻单核苷酸多态性及其应用现状

单核苷酸多态性（single nucleotide polymorphisms, SNPs）在水稻中数量多,分布密度高,遗传稳定性高。水稻SNPs的发现方法主要有对样本DNA的PCR产物直接测序、从SSR区段检测SNPs和从基因组序列直接搜索等。目前已有多种基因分型技术运用到了水稻SNPs检测,SNPs检测的高度自动化使水稻SNPs基因分型非常方便。单核苷酸多态性在水稻遗传图谱的构建、基因克隆和功能基因组学研究、标记辅助选择育种、遗传资源分类及物种进化等方面的应用具有巨大潜力。     

IL-1β基因单核苷酸多态性与腰椎间盘疾病的相关性

为研究汉族人白细胞介素-1β(IL-1β)基因-511T＞C和 3954C＞T位点单核苷酸多态性与腰椎间盘疾病的关系,采用聚合酶链反应技术,扩增81例腰椎间盘疾病患者和101例正常对照者中分别包含IL-1β基因-511T＞C和 3954C＞T位点的片段,酶切法鉴定IL-1β基因-51iT＞C和 3954C＞T位点单核苷酸多态性情况,比较两组中基因多态性与腰椎间盘疾病的关系.同时,利用MRI检测两组腰椎间盘退变的情况,并分析其中小于45岁者IL-1β基因多态性与腰椎间盘退变严重程度的关系.结果显示,腰椎间盘疾病病例组及对照组中均存在IL-1β基因-511T＞C和 3954C＞T位点单核苷酸多态性.IL-1β基因-511T＞C位点TT、TC和CC基因型,T,C基因型差别与腰椎间盘疾病有关(P＜0.01),与腰椎间盘退变严重程度无关(P＞0.05),但IL-1β基因 3954C＞T位点单核苷酸多态性与腰椎间盘退变严重程度及腰椎间盘疾病均无关(P＞0.05).表明在汉族人中,存在IL-1β基因-511T＞C和 3954C＞T位点单核苷酸多态性,但仅-511T＞C位点单核苷酸多态性与腰椎间盘疾病有关.     

癫痫患儿SCN1A、MDR1 G2677TA、ABCB1 C3435T基因多态性与左乙拉西坦治疗效果的关系及疗效的影响因素分析

摘要 目的：探讨癫痫患儿SCN1A、MDR1 G2677TA、ABCB1 C3435T基因多态性与左乙拉西坦（LEV）治疗效果的关系及疗效的影响因素。方法：选择2019年6月至2021年7月在本院接受LEV治疗的癫痫患儿226例为研究对象,分析所有患儿基因型和等位基因分布情况;治疗3个月后根据治疗效果分为有效组和无效组,分析两组患儿SCN1A、MDR1 G2677TA、ABCB1 C3435T基因型及等位基因频率分布;采用单因素及多因素Logistic回归分析法分析影响临床疗效的因素。结果：癫痫患儿SCN1A rs4667869、SCN1A rs10497275、MDR1 G2677TA、ABCB1 C3435T基因型及等位基因分布频率有统计学差异（P＜0.05）。有效组SCN1A rs4667869的基因型GG、GC及等位基因G分布频率高于无效组（P＜0.05）,基因型CC及等位基因C分布频率低于无效组（P＜0.05）;有效组SCN1A rs10497275的基因型GA及等位基因G高于无效组（P＜0.05）,基因型AA及等位基因A分布频率低于无效组（P＜0.05）;有效组MDR1 G2677TA的基因型GT、TT及等位基因T高于无效组（P＜0.05）,基因型GG、AA及等位基因G分布频率低于无效组（P＜0.05）;有效组ABCB1 C3435T的基因型CC、CT及等位基因C分布频率高于无效组（P＜0.05）,基因型TT及等位基因T分布频率低于无效组（P＜0.05）。单因素分析显示,月发作频率和出生窒息史与LEV治疗癫痫患儿疗效有关。多因素Logistic回归分析显示,SCN1A rs4667869、SCN1A rs10497275、MDR1 G2677TA和ABCB1 C3435T基因型及等位基因、出生窒息史是LEV治疗癫痫患儿疗效的影响因素。结论：癫痫患儿SCN1A、MDR1 G2677TA和ABCB1 C3435T基因多态性与LEV治疗效果有关,其多种基因型是LEV治疗效果的影响因素。     

MDR1 Gene Polymorphisms and Clinical Relevance

In vivo and in vitro studies have demonstrated that P-glycoprotein (P-gp) plays a very significant role in the ADME processes (absorption, distribution, metabolism, excretion) and drug-drug interaction (DDI) of drugs in humans. P-gp is the product of multidrug resistance gene (MDR1/ABCB1). Pharmacogenomics and pharmacogenetics studies have revealed that genetic polymorphisms of MDR1 are associated with alteration in P-gp expression and function in different ethnicities and subjects. By now, 50 single nucleotide polymorphisms (SNPs) and 3 insertion/deletion polymorphisms have been found in the MDR1 gene. Some of them, such as C3435T, have been identified to be a risk factor for numerous diseases. It is believed that further understanding of the physiology and biochemistry of P-gp with respect to its genetic variations may be important for individualized pharmacotherapy. Therefore, based on the latest public information and our studies, this review focuses on the following four aspects: 1) the impact of P-gp on pharmacokinetics; 2) MDR1 genetic polymorphisms and their impacts on pharmacogenetics; 3) relationship between altered P-gp expression and function and the MDR1^C3435T SNP, and 4) relevance of MDR1 polymorphisms to certain human diseases.     

The role of Multidrug Resistance-1 (MDR1) variants in response to atorvastatin among Jordanians

The MDR1 gene encodes for P-glycoprotein (P-gp), which is an efflux transporter at the cell membrane. The P-gp has wide substrate specificity for multiple medications including the lipid lowering drug, atorvastatin. In this study, we investigated the possible association between three common MDR1 gene polymorphisms (G2677T, C3435T, and C1236T), and the lipid lowering effect of atorvastatin among Jordanians. Lipid and lipoproteins were measured in blood samples collected from patients (n = 201) at baseline and during atorvastatin treatment. MDR1 polymorphisms were genotyped using polymerase chain reaction–restriction fragment length polymorphism. Both the TT genotype of G2677T and the TT genotype of the C3435T polymorphisms were associated with lower levels of low-density lipoproteins after atorvastatin treatment. However, the effects of atorvastatin on the levels of total cholesterol, triglycerides, and high-density lipoprotein, were not correlated with any of the genotypes in both polymorphisms. Finally, the C1236T polymorphism was not associated with the lipid lowering effect of atorvastatin. In conclusion, the MDR1 gene polymorphisms G2677T, and C3435T, but not C1236T were associated with the lipid lowering effect of atorvastatin among Jordanians.     

Association of MDR1 C3435T polymorphism with bipolar disorder in patients treated with valproic acid

P-glycoprotein (P-gp), an efflux transporter protein, is an ABC transporter encoded by the multidrug resistance 1 gene (MDR1, ABCB1). The common synonymous C3435T polymorphism in exon 26 is reported to associate with lower P-gp functional expression and drug uptake. Many extended pharmacogenomics, functional, and complex disease association studies focused mainly on this polymorphism. We investigated the association of exon 26 C3435T genetic variants of MDR1 gene with susceptibility to bipolar disorder and serum valproic acid concentration. Totally, 104 patients meeting DSM-IV criteria for bipolar disorder and 169 controls were admitted to the study. There was statistically significant difference between the genotypes of bipolar patients (CT 91.2%, TT 6.8%, and CC 2%) and controls (CT 52.7%, TT 26%, CC 21.3%) although their allelic distribution was similar. The serum valproic acid concentrations of the patients with CT, TT and CC genotypes were 72.92 ± 20.55, 80.47 ± 14.01 and 68.29 ± 12.17 μg/ml, respectively, and there was no significant difference between the C3435T genotypes.     

The association of MDR1 C3435T and G2677T/A polymorphisms with plasma platelet-activating factor levels and coronary artery disease risk in Turkish population

Increased levels of peripheral proinflammatory mediators can contribute to the development of coronary artery disease (CAD). Platelet activating factor (PAF) is an important proinflammatory mediator and plasma levels of PAF correlate with transmembrane transporter multidrug resistant 1 P-glycoprotein (MDR1 Pgp) expression and activity. MDR1 polymorphisms can affect the expression and activity of Pgp and plasma PAF levels. Therefore, we investigated the possible relationship between MDR1 C3435T and G2677T/A polymorphisms and plasma PAF levels and the risk of CAD. The study population consisted of 198 patients angiographically documented CAD, including 113 cases with at least 1 coronary artery with ≥ 50% luminal diameter stenosis and 85 control subjects with strictly normal coronary angiograms. Genotypes of the MDR1 C3435T and G2677T/A polymorphisms were determined by polymerase chain reaction (PCR) followed by restriction fragment length polymorphism (RFLP). Plasma PAF levels were detected by enzyme-linked immunosorbent assay (ELISA). There were no significant differences among plasma PAF levels in regard to MDR1 C3435T and G2677T polymorphisms in CAD patients and controls. No statistically significant difference was found for the genotypic and allelic distributions of the polymorphisms in the MDR1 gene between the patients and the control subjects. Furthermore, analysis of MDR1 haplotypes did not show any associations with increased plasma PAF levels and risk of CAD. Our results suggest that plasma PAF levels are not associated with MDR1 gene polymorphisms. There is no association between MDR1 C3435T and G2677T/A polymorphisms and the risk of CAD in Turkish patients.     

Polymorphism C3435T of the MDR1 gene in Central Americans and Spaniards

The human multidrug resistance gene (MDR1) encodes for P-glycoprotein (P-gp) which is a transmembrane transporter protein that acts as an efflux pump for a number of lypophilic compounds. It plays a protective role for cells against DNA damage. The wobble C3435T polymorphism at exon 26 has been associated with different expression levels and activity. Differences in allele frequency of the C3435T polymorphism have been demonstrated between distinct ethnic groups. In our study we examined these polymorphisms in 433 healthy individuals. From these, 229 were Central American mestizos from Nicaragua (n = 117) and El Salvador (n = 112) to be compared with a group of 204 North Spaniards, with the aim of detecting potential genotypic differences between these populations. The genotypes were determined by PCR-RFLP. The frequencies of the C allele were very similar among Central Americans (0.53) and Spaniards (0.52), which is consistent with the ethnic origin of Central American individuals (Amerindians and European Caucasians). In comparison to other previously studied populations, the C allele frequency in Central Americans was significantly lower than that found in African populations and higher than that observed in the Indian and Southwest Asian populations. These data may be relevant for dose recommendation of P-gp substrate drugs and also for studies of allele disease association in the Central American population.     

MDR1 mRNA expression and MDR1 gene variants as predictors of response to chemotherapy in patients with acute myeloid leukaemia: a meta-analysis

Abstract

Data from 30 pharmacogenomic studies that investigated MDR1 mRNA expression or gene variants (C3435T, G2677TA, C1236T) and response to therapy in acute myeloid leukaemia (AML) were synthesized. Anthracycline-based regimens were mainly used. MDR1 mRNA overexpression was associated with poor response to therapy [odds ratio (OR)?=?2.49 95% confidence interval (CI) 1.38–4.50]. The gene variants were not associated with response to treatment; the generalized ORs, a genetic model-free approach, for the variants C3435T, G2677TA and C1236T were OR_G?=?0.86 (95% CI 0.55–1.37), OR_G?=?0.97 (95% CI 0.58–1.64) and OR_G?=?1.17 (95% CI 0.75--1.83), respectively. There is indication that MDR1 mRNA expression may be considered as a potential marker for response to chemotherapy in AML patients.     

MDR1 gene polymorphisms may be associated with Behçet's disease and its colchicum treatment response

Behçet's disease (BD) is a chronic multisystem disorder. Infectious agents, immune system mechanisms, and genetic factors are implicated in the etiopathogenesis of BD, which remains to be explained. The human MDR1 (ABCB1) gene encoder P-glycoprotein (P-gp) plays a key role in drug disposition, serves as a protective mechanism against xenobiotics, and provides additional protection for the brain, testis, and fetus. We investigated the genotype and haplotype distributions of three MDR1 gene polymorphisms (C1236T, G2677T/A, and C3435T) in 104 BD patients and 130 control subjects. The genotyping analysis was performed by using PCR–RFLP methods.     

The drug-transporter gene MDR1 C3435T and G2677T/A polymorphisms and the risk of multidrug-resistant epilepsy in Turkish children

One-third of all individuals with epilepsy are resistant to antiepileptic drug (AED) treatment. Antiepileptic treatment response has been suggested to be modulated by genetic polymorphisms of drug efflux transporters. Several polymorphic variants within the multidrug resistance 1 (MDR1) gene, which encodes the major transmembrane efflux transporter P-glycoprotein, have been proposed to be associated with AED resistance in epilepsy patients. The aim of this study was to evaluate the effect of C3435T and G2677T/A polymorphisms of MDR1 on AED resistance in Turkish children with epilepsy. MDR1 C3435T and G2677T/A were genotyped in 152 patients with epilepsy, classified as drug-resistant in 69 and drug-responsive in 83. Genotypes of the C3435T and G2677T/A polymorphisms were determined by polymerase chain reaction followed by restriction fragment length polymorphism. Genotype and allele frequencies of C3435T and G2677T/A polymorphisms of the MDR1 gene did not differ between drug-resistant and drug-responsive epilepsy patients. Our results suggest that MDR1 C3435T and G2677T/A polymorphisms are not associated with AED resistance in Turkish epileptic patients. To clarify the exact clinical implication of the MDR1 polymorphisms on the multidrug resistance in epilepsy, further investigations in various ethnic populations would be necessary.     

Genotype and allele frequency of human multidrug resistance (MDR1) gene C3435T polymorphism in Denizli province of Turkey

Human p-glycoprotein encoded by human multidrug resistance (MDR1) gene, is a transmembrane protein that serves as efflux pump for a wide variety of lipophilic compounds possessing a physiological role in protecting cells against the DNA damaging of certain xenobiotics. According to the published data, the frequency of C3435T polymorphism differs depending on the different ethnical populations such as Asian, African, and Caucasians populations. In our study, we identified the MDR1 C3435T polymorphism in 150 healthy volunteers in Denizli province of Turkey. DNA was extracted from peripheral blood samples by standard phenol/chloroform extraction method. Polymerase chain reaction–restriction fragment length polymorphism was used for the detection of C3435T single nucleotide polymorphism. We obtained CC, CT and TT genotype frequencies as 20, 53 and 27%, respectively. According to our results, the C allele in Turkish population (Denizli province, west of Turkey) is found 47% and this data shows similarity with Caucasian (UK and German) populations and significantly lower than African populations (p < 0.001). Our study is the first data on the genotype and allele frequency of the human multidrug resistance (MDR1) Gene C3435T Polymorphism in Denizli Province at regional basis in Turkey. Our results could serve as a basis for large-scale correlation studies on the relevance of C3435T genotype in cancer therapy and other diseases in Turkish population. Investigation of genotype frequencies related with p-glycoprotein substrates should be investigated in large scale at regional bases in Turkish population. The scaled-up data might help either to the use of p-glycoprotein substrates to be used for therapeutic applications and population genetics considering the genotype frequencies possibly occurring throughout the history in Anatolian basin.     

MDR1 C3435T polymorphism and cancer risk: a meta-analysis based on 39 case–control studies

Multidrug resistance 1 (MDR1) gene encodes the ATP-dependent cellular efflux pump P-glycoprotein (P-gp) which efflux of a variety of substances across the membrane. P-gp could serve a role in cancer etiology based on its physiological role of protecting cells from xenobiotics or metabolites. The C3435T (rs1045642) polymorphism of the MDR1 gene which could influence the P-gp expression and function have been implicated in the cancer risk. However, the results from the published studies on the association between this polymorphism and cancer risk are conflicting. To drive a more precise estimation of this association, we performed a meta-analysis of 39 case-control studies, including a total of 9,265 cancer cases and 13,502 controls. We used odds ratios (ORs) with their 95% confidence intervals (CIs) to assess the strength of the association. Overall, individuals with the MDR1 3435TT genotype were associated with an increased cancer risk than those with the CC (OR = 1.29, 95% CI: 1.10-1.51) or CT/CC (OR = 1.18, 95% CI: 1.04-1.34) genotypes, similar to the CT or CT/TT compared with the CC genotype. In the stratified analyses, the increased risks were more pounced among hematologic malignances (OR = 1.27, 95% CI: 1.10-1.46, P (heterogeneity) = 0.415), breast cancer (1.42, 1.04-1.94, 0.018), renal cancer (1.77, 1.28-2.46, 0.307), Caucasians (1.21, 1.07-1.38, 0.000) and population-based studies (1.20, 1.05-1.36, 0.000) in a dominant model. The results suggested that the MDR1 C3435T polymorphism may contribute to cancer risk.